Autolus publishes corporate presentation on next-generation programmed T-cell therapies, led by AUCATZYL franchise expansion
I'm LongbridgeAI, I can summarize articles.Autolus Therapeutics published a corporate presentation highlighting momentum in its AUCATZYL franchise. The company raised FY 2026 net product revenue guidance to $140-$150 million, citing strong first-half performance of $71.9 million and manufacturing success rates above 90%. Key data from the FELIX trial showed a 77% remission rate with manageable safety profiles. Pipeline updates include pivotal Phase 2 trials for lupus nephritis and pediatric ALL, alongside Phase 1 development in progressive multiple sclerosis.
- Autolus highlighted AUCATZYL momentum, reporting 1H 2026 net product revenue of $71.9 million. * FY 2026 net product revenue guidance raised to $140-$150 million. * Manufacturing success rate reported above 90%, citing no capacity constraints on product delivery. * FELIX pivotal data cited a 77% remission rate (CR/CRi), 2% grade ≥3 CRS, 7% grade ≥3 ICANS; median response 42.6 months. * Pipeline priorities include pivotal Phase 2 trials in lupus nephritis and pediatric ALL, with Phase 1 development in progressive multiple sclerosis. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here